ConductScience.org, home

Paper206648

Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis.

Lennon VA and 4 others. J Exp Med, 1978. Cited by 231 papers, by iCite.

Cite this record

ConductScience Library. Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis. Papers, record 206648. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/206648

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis.
PubMed
Journal
J Exp Med
PubMed
Year
1978
PubMed
Publication types
Journal Article, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
231
iCite
Relative citation ratio, by iCite
5.68
iCite
Revised in PubMed
2019-05-08
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Lennon VAV A
2Seybold MEM E
3Lindstrom JMJ M
4Cochrane CC
5Ulevitch RR

Source PubMed

Download CSV of authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Autoimmune DiseasesMajor topic
Complement System ProteinsMajor topic
Myasthenia GravisMajor topic
Animals
Antibodies
Complement C3
Elapid Venoms
Immunization, Passive
Neuromuscular Junction
Rats
Receptors, Nicotinic
Synaptic Membranes
Synaptic Transmission

Source PubMed

Download CSV of topics

References23

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
163374Antigen, host and adjuvant requirements for induction of hyperacute experimental autoimmune encephalomyelitis.Eur J Immunol1976https://conductscience.org/library/papers/63374PubMed
261167Immunology of the acetylcholine receptor.Immunol Commun1976https://conductscience.org/library/papers/61167PubMed
3396104Complement receptors.Contemp Top Mol Immunol1977https://conductscience.org/library/papers/396104PubMed
4268657Modulation of acetylcholine receptor by antibody against the receptor.Proc Natl Acad Sci U S A1977https://conductscience.org/library/papers/268657PubMed
5557772Ultrastructural localization of the acetylcholine receptor in myasthenia gravis and in its experimental autoimmune model.Neurology1977https://conductscience.org/library/papers/557772PubMed
6870771Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations.Mayo Clin Proc1977https://conductscience.org/library/papers/870771PubMed
7865619Human myasthenic sera reduce acetylcholine sensitivity of human muscle cells in tissue culture.Nature1977https://conductscience.org/library/papers/865619PubMed
8865618Myasthenia gravis serum reduces acetylcholine sensitivity in cultured rat myotubes.Nature1977https://conductscience.org/library/papers/865618PubMed
9831074Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice.N Engl J Med1977https://conductscience.org/library/papers/831074PubMed
10830746Cytophilic antibodies in experimental autoimmune myasthenia gravis.J Immunol1977https://conductscience.org/library/papers/830746PubMed
114981797Two anticomplementary factors in cobra venom: hemolysis of guinea pig erythrocytes by one of them.J Immunol1969https://conductscience.org/library/papers/4981797PubMed
12182897Pathological mechanisms in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine recepotr antibodies.J Exp Med1976https://conductscience.org/library/papers/182897PubMed
13182896
Pathological mechanisms in experimental autoimmune myasthenia gravis. I. Immunogenicity of syngeneic muscle acetylcholine receptor and quantitative extraction of receptor and antibody-receptor complexes from muscles of rats with experimental automimmune myasthenia gravis.
J Exp Med1976https://conductscience.org/library/papers/182896PubMed
14803234Inhibition of experimental autoimmune renal tubulointerstitial disease in guinea pigs by depletion of complement with cobra venom factor.Clin Immunol Immunopathol1975https://conductscience.org/library/papers/803234PubMed
155287835The syndrome of myasthenia and polymyositis with comments on therapy.Ann N Y Acad Sci1971https://conductscience.org/library/papers/5287835PubMed
161085587Experimental autoimmune myasthenia gravis: cellular and humoral immune responses.Ann N Y Acad Sci1976https://conductscience.org/library/papers/1085587PubMed
171066997The motor end plate in myasthenia gravis and in experimental autoimmune myasthenia gravis. A quantitative ultrastructural study.Ann N Y Acad Sci1976https://conductscience.org/library/papers/1066997PubMed
181066989Experimental autoimmune myasthenia: clinical, neurophysiologic, and pharmacologic aspects.Ann N Y Acad Sci1976https://conductscience.org/library/papers/1066989PubMed
191066988Experimental autoimmune myasthenia gravis and myasthenia gravis: biochemical and immunochemical aspects.Ann N Y Acad Sci1976https://conductscience.org/library/papers/1066988PubMed
201257792Complement-dependent immunoglobulin G receptor function in lymphoid cells.Science1976https://conductscience.org/library/papers/1257792PubMed

See all 23 referencesDownload CSV of references

Cited by61

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 231 citations.

PMIDTitleJournalYearIn PapersSource
42693185Role of complement and complement-targeted therapeutics in neurological diseases.Nat Rev Neurol2026https://conductscience.org/library/papers/42693185PubMed
40896413Emerging role of complement system in the induction of neuroinflammation in adenylosuccinate lyase deficiency disorder.Brain Behav Immun Health2025https://conductscience.org/library/papers/40896413PubMed
40519165Friend or foe: assessing the value of animal models for facilitating clinical breakthroughs in complement research.J Clin Invest2025https://conductscience.org/library/papers/40519165PubMed
40410792Diverse cell types establish a pathogenic immune environment in peripheral neuropathy.J Neuroinflammation2025https://conductscience.org/library/papers/40410792PubMed
40279038Causal Variants in CHRNA1 and CHRNB1 Genes for Anti-acetylcholine Receptor Antibody Positive Myasthenia Gravis: Evidence from Bayesian Fine-Mapping and Genetic Association Study.Mol Neurobiol2025https://conductscience.org/library/papers/40279038PubMed
38789789Treating myasthenia gravis beyond the eye clinic.Eye (Lond)2024https://conductscience.org/library/papers/38789789PubMed
38133144Pathophysiology of Childhood-Onset Myasthenia: Abnormalities of Neuromuscular Junction and Autoimmunity and Its Background.Pathophysiology2023https://conductscience.org/library/papers/38133144PubMed
37869140Role of complement in myasthenia gravis.Front Neurol2023https://conductscience.org/library/papers/37869140PubMed
35553024Anti-complement Agents for Autoimmune Neurological Disease.Neurotherapeutics2022https://conductscience.org/library/papers/35553024PubMed
34233932Characterization of LRP4/Agrin Antibodies From a Patient With Myasthenia Gravis.Neurology2021https://conductscience.org/library/papers/34233932PubMed
33114553Precision Medicine in Neurology: The Inspirational Paradigm of Complement Therapeutics.Pharmaceuticals (Basel)2020https://conductscience.org/library/papers/33114553PubMed
32582144Complement Inhibitor Therapy for Myasthenia Gravis.Front Immunol2020https://conductscience.org/library/papers/32582144PubMed
31482201Role of complement and potential of complement inhibitors in myasthenia gravis and neuromyelitis optica spectrum disorders: a brief review.J Neurol2021https://conductscience.org/library/papers/31482201PubMed
31193726Investigational RNAi Therapeutic Targeting C5 Is Efficacious in Pre-clinical Models of Myasthenia Gravis.Mol Ther Methods Clin Dev2019https://conductscience.org/library/papers/31193726PubMed
30524436Complement-Activating Capacity of Autoantibodies Correlates With Disease Activity in Bullous Pemphigoid Patients.Front Immunol2018https://conductscience.org/library/papers/30524436PubMed
30010142New Pathways and Therapeutic Targets in Autoimmune Myasthenia Gravis.J Neuromuscul Dis2018https://conductscience.org/library/papers/30010142PubMed
28184292Rituximab therapy in pemphigus and other autoantibody-mediated diseases.F1000Res2017https://conductscience.org/library/papers/28184292PubMed
27019601Animal models of myasthenia gravis: utility and limitations.Int J Gen Med2016https://conductscience.org/library/papers/27019601PubMed
26632886The African-387 C>T TGFB1 variant is functional and associates with the ophthalmoplegic complication in juvenile myasthenia gravis.J Hum Genet2016https://conductscience.org/library/papers/26632886PubMed
26510558Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis.Neurotherapeutics2016https://conductscience.org/library/papers/26510558PubMed

See all 61 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
C3718PubTator's text mininghttps://conductscience.org/library/genes/718

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/206648

GET https://conductscience.org/api/papers/v1/206648/references?page=2